title: Using molecular markers to help predict who will fail after radical prostatectomy.
abstract: Recent phase III trial data clearly demonstrate that adjuvant therapy can reduce recurrence and increase survival after prostatectomy for prostate cancer. There is great interest in being able to accurately predict who is at risk of failure to avoid treating those who may not benefit. The standard markers consisting of prostate specific antigen (PSA), Gleason score, and pathological stage are not very specific, so there is an unmet need for other markers to aid in prognostic stratification. Numerous studies have been conducted with various markers and more recently gene signatures, but it is unclear whether any of them are really useful. We conducted a comprehensive review of the literature to determine the current status of molecular markers in predicting outcome after radical prostatectomy.
authors.affiliation: Departments of Radiation Oncology, Radiology, and Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive MC 7889, San Antonio, TX 78229, USA.
authors.forename: Gregory P
authors.initials: GP
authors.lastname: Swanson
authors.forename: David
authors.initials: D
authors.lastname: Quinn
references.citation: Cancer Res. 2000 Mar 15;60(6):1585-94
references.pmid: 10749127
references.citation: Oncogene. 2006 Feb 16;25(7):1090-8
references.pmid: 16247466
references.citation: Cancer. 2000 Jan 15;88(2):416-24
references.pmid: 10640976
references.citation: Cancer. 1997 Mar 1;79(5):952-62
references.pmid: 9041158
references.citation: J Clin Oncol. 2004 Jul 15;22(14):2790-9
references.pmid: 15254046
references.citation: Nature. 2001 Aug 23;412(6849):822-6
references.pmid: 11518967
references.citation: Int J Cancer. 1983 Jan 15;31(1):13-20
references.pmid: 6339421
references.citation: J Urol. 1997 Jul;158(1):131-7
references.pmid: 9186339
references.citation: Br J Cancer. 1999 Nov;81(6):1052-8
references.pmid: 10576664
references.citation: J Clin Oncol. 1999 May;17(5):1499-507
references.pmid: 10334537
references.citation: Scand J Urol Nephrol. 2009;43(1):12-8
references.pmid: 18949633
references.citation: Scand J Urol Nephrol. 2007;41(5):375-81
references.pmid: 17853019
references.citation: PLoS One. 2008;3(5):e2318
references.pmid: 18846227
references.citation: N Engl J Med. 2004 Dec 30;351(27):2817-26
references.pmid: 15591335
references.citation: Cancer. 1997 Jun 1;79(11):2162-70
references.pmid: 9179063
references.citation: Clin Cancer Res. 2008 Jun 1;14(11):3395-400
references.pmid: 18519769
references.citation: Int J Cancer. 1999 Oct 22;84(5):478-83
references.pmid: 10502724
references.citation: Urology. 2003 Jun;61(6):1187-92
references.pmid: 12809895
references.citation: Clin Cancer Res. 1999 May;5(5):977-83
references.pmid: 10353729
references.citation: Clin Cancer Res. 2003 Apr;9(4):1474-9
references.pmid: 12684422
references.citation: Br J Cancer. 2007 Sep 3;97(5):678-85
references.pmid: 17700571
references.citation: BMC Med Genomics. 2008 Apr 25;1:11
references.pmid: 18439262
references.citation: J Clin Invest. 2004 Mar;113(6):913-23
references.pmid: 15067324
references.citation: Lancet Oncol. 2011 Mar;12(3):245-55
references.pmid: 21310658
references.citation: Oncogene. 2005 May 26;24(23):3847-52
references.pmid: 15750627
references.citation: Cancer Res. 1999 May 15;59(10):2324-8
references.pmid: 10344737
references.citation: BMC Cancer. 2008 Aug 11;8:230
references.pmid: 18694509
references.citation: J Clin Invest. 2000 Jan;105(1):3-7
references.pmid: 10619854
references.citation: Surgery. 1996 Aug;120(2):159-66; discussion 166-7
references.pmid: 8751578
references.citation: J Urol. 1998 Mar;159(3):941-5
references.pmid: 9474188
references.citation: Cancer Res. 2003 Jul 15;63(14):4196-203
references.pmid: 12874026
references.citation: J Urol. 1999 Apr;161(4):1238-43
references.pmid: 10081877
references.citation: Clin Cancer Res. 2001 Mar;7(3):544-50
references.pmid: 11297246
references.citation: Cancer. 2005 Jul 15;104(2):290-8
references.pmid: 15948174
references.citation: Cancer Res. 2006 Sep 1;66(17):8347-51
references.pmid: 16951141
references.citation: Nature. 2002 Oct 10;419(6907):624-9
references.pmid: 12374981
references.citation: J Natl Cancer Inst. 1997 Aug 20;89(16):1224-7
references.pmid: 9274918
references.citation: J Urol. 2003 Jul;170(1):78-81
references.pmid: 12796649
references.citation: Urology. 2008 Jul;72(1):167-71
references.pmid: 18384856
references.citation: J Urol. 2000 Dec;164(6):2156-61
references.pmid: 11061947
references.citation: Cancer. 1997 Aug 15;80(4):753-63
references.pmid: 9264360
references.citation: Am J Pathol. 1996 May;148(5):1557-65
references.pmid: 8623924
references.citation: Int J Cancer. 2008 Feb 1;122(3):595-602
references.pmid: 17943722
references.citation: J Urol. 1996 Mar;155(3):982-5
references.pmid: 8583622
references.citation: Eur J Cancer. 1998 Apr;34(5):679-86
references.pmid: 9713274
references.citation: J Natl Cancer Inst. 2003 May 7;95(9):661-8
references.pmid: 12734317
references.citation: Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6
references.pmid: 14711987
references.citation: Eur Urol. 2001 Nov;40(5):495-503
references.pmid: 11752855
references.citation: J Clin Oncol. 2005 Oct 1;23(28):7005-12
references.pmid: 16192588
references.citation: Clin Cancer Res. 2007 Dec 1;13(23):7003-11
references.pmid: 18056176
references.citation: Prostate. 2007 May 1;67(6):614-22
references.pmid: 17299799
references.citation: Clin Cancer Res. 1999 Aug;5(8):2082-8
references.pmid: 10473090
references.citation: J Clin Oncol. 2006 Jan 10;24(2):268-73
references.pmid: 16330673
references.citation: Eur Urol. 2005 Nov;48(5):745-51
references.pmid: 16139948
references.citation: Cancer Res. 1999 Nov 15;59(22):5719-23
references.pmid: 10582690
references.citation: Br J Cancer. 2007 Dec 17;97(12):1690-5
references.pmid: 17971772
references.citation: Cancer Res. 1998 Feb 1;58(3):542-8
references.pmid: 9458103
references.citation: N Engl J Med. 2007 Jul 5;357(1):39-51
references.pmid: 17611206
references.citation: Cancer Res. 2009 Feb 15;69(4):1400-6
references.pmid: 19190343
references.citation: Urol Oncol. 2010 Mar-Apr;28(2):145-51
references.pmid: 18848789
references.citation: J Urol. 1996 Sep;156(3):1064-8
references.pmid: 8709308
references.citation: J Urol. 1996 Oct;156(4):1511-6
references.pmid: 8808919
references.citation: Br J Urol. 1998 Mar;81(3):406-12
references.pmid: 9523661
references.citation: J Clin Oncol. 1998 Apr;16(4):1302-9
references.pmid: 9552030
references.citation: J Pathol. 1996 Apr;178(4):437-41
references.pmid: 8691323
references.citation: Hum Pathol. 2001 Jul;32(7):690-7
references.pmid: 11486167
references.citation: J Natl Cancer Inst. 2006 Oct 4;98(19):1420-4
references.pmid: 17018789
references.citation: Mod Pathol. 2008 Dec;21(12):1451-60
references.pmid: 18500259
references.citation: Cancer. 2003 Mar 1;97(5):1225-33
references.pmid: 12599229
references.citation: N Engl J Med. 2009 Feb 19;360(8):790-800
references.pmid: 19228622
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1424-32
references.pmid: 15941951
references.citation: Asian J Androl. 2009 Jan;11(1):109-18
references.pmid: 19050681
references.citation: Nature. 2005 Jun 30;435(7046):1262-6
references.pmid: 15988529
references.citation: J Natl Cancer Inst. 1998 Jun 17;90(12):916-20
references.pmid: 9637141